Convergent Clonal Evolution of Signaling Gene Mutations Is a Hallmark of Myelodysplastic Syndrome Progression

Overview

Journal Blood Cancer Discov

Specialties Hematology
Oncology

Date 2022 Jun 16

PMID 35709710

Authors

Andrew J Menssen

Ajay Khanna

Christopher A Miller

Sridhar Nonavinkere Srivatsan

Gue Su Chang

Jin Shao

Joshua Robinson

Michele OLaughlin

Catrina C Fronick

Robert S Fulton

Kimberly Brendel

Sharon E Heath

Raya Saba

John S Welch

David H Spencer

Jacqueline E Payton

Peter Westervelt

John F Dipersio

Daniel C Link

Matthew J Schuelke

Meagan A Jacoby

Eric J Duncavage

Timothy J Ley

Matthew J Walter

Affiliations

Soon will be listed here.

Abstract

Significance: Subclone expansion is a hallmark of progression from MDS to secondary AML. Subclonal signaling gene mutations are common at MDS (often at low levels), show complex and convergent patterns of clonal evolution, and are associated with future progression to secondary AML. See related article by Guess et al., p. 316 (33). See related commentary by Romine and van Galen, p. 270. This article is highlighted in the In This Issue feature, p. 265.

Citing Articles

RAS-mutant leukaemia stem cells drive clinical resistance to venetoclax.

Sango J, Carcamo S, Sirenko M, Maiti A, Mansour H, Ulukaya G Nature. 2024; 636(8041):241-250.

PMID: 39478230 PMC: 11618090. DOI: 10.1038/s41586-024-08137-x.

Monitoring clonal burden as an alternative to blast count for myelodysplastic neoplasm treatment response.

Jacoby M, Duncavage E, Khanna A, Chang G, Nonavinkere Srivatsan S, Miller C Leukemia. 2024; 39(1):166-177.

PMID: 39367170 DOI: 10.1038/s41375-024-02426-0.

Comprehensive sequential genetic analysis delineating frequency, patterns, and prognostic impact of genomic dynamics in a real-world cohort of patients with lower-risk MDS.

Mazzeo P, Ganster C, Wiedenhoft J, Shirneshan K, Rittscher K, Brzuszkiewicz E Hemasphere. 2024; 8(9):e70014.

PMID: 39315323 PMC: 11417473. DOI: 10.1002/hem3.70014.

A Brief Overview of the Molecular Landscape of Myelodysplastic Neoplasms.

Abdulbaki R, Pullarkat S Curr Oncol. 2024; 31(5):2353-2363.

PMID: 38785456 PMC: 11119831. DOI: 10.3390/curroncol31050175.

Single-cell Multiomics Analysis of Myelodysplastic Syndromes and Clinical Response to Hypomethylating Therapy.

Campillo-Marcos I, Casado-Pelaez M, Davalos V, Ferrer G, Mata C, Mereu E Cancer Res Commun. 2024; 4(2):365-377.

PMID: 38300528 PMC: 10860538. DOI: 10.1158/2767-9764.CRC-23-0389.

References

Miller C, White B, Dees N, Griffith M, Welch J, Griffith O . SciClone: inferring clonal architecture and tracking the spatial and temporal patterns of tumor evolution. PLoS Comput Biol. 2014; 10(8):e1003665. PMC: 4125065. DOI: 10.1371/journal.pcbi.1003665. View

Takahashi K, Jabbour E, Wang X, Luthra R, Bueso-Ramos C, Patel K . Dynamic acquisition of FLT3 or RAS alterations drive a subset of patients with lower risk MDS to secondary AML. Leukemia. 2013; 27(10):2081-3. DOI: 10.1038/leu.2013.165. View

Jacoby M, Duncavage E, Chang G, Miller C, Shao J, Elliott K . Subclones dominate at MDS progression following allogeneic hematopoietic cell transplant. JCI Insight. 2018; 3(5). PMC: 5922277. DOI: 10.1172/jci.insight.98962. View

Corces-Zimmerman M, Hong W, Weissman I, Medeiros B, Majeti R . Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. Proc Natl Acad Sci U S A. 2014; 111(7):2548-53. PMC: 3932921. DOI: 10.1073/pnas.1324297111. View

Ortmann C, Kent D, Nangalia J, Silber Y, Wedge D, Grinfeld J . Effect of mutation order on myeloproliferative neoplasms. N Engl J Med. 2015; 372(7):601-612. PMC: 4660033. DOI: 10.1056/NEJMoa1412098. View

Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, Yamamoto R . Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011; 478(7367):64-9. DOI: 10.1038/nature10496. View

Klco J, Miller C, Griffith M, Petti A, Spencer D, Ketkar-Kulkarni S . Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid Leukemia. JAMA. 2015; 314(8):811-22. PMC: 4621257. DOI: 10.1001/jama.2015.9643. View

Borthakur G, Lin E, Jain N, Estey E, Cortes J, OBrien S . Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia. Cancer. 2009; 115(14):3217-21. PMC: 4184418. DOI: 10.1002/cncr.24367. View

Hulegardh E, Nilsson C, Lazarevic V, Garelius H, Antunovic P, Rangert Derolf A . Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: a report from the Swedish Acute Leukemia Registry. Am J Hematol. 2014; 90(3):208-14. DOI: 10.1002/ajh.23908. View

10.

Geskus R . Cause-specific cumulative incidence estimation and the fine and gray model under both left truncation and right censoring. Biometrics. 2010; 67(1):39-49. DOI: 10.1111/j.1541-0420.2010.01420.x. View

11.

Morita K, Wang F, Jahn K, Hu T, Tanaka T, Sasaki Y . Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. Nat Commun. 2020; 11(1):5327. PMC: 7577981. DOI: 10.1038/s41467-020-19119-8. View

12.

Welch J . Mutation position within evolutionary subclonal architecture in AML. Semin Hematol. 2014; 51(4):273-81. DOI: 10.1053/j.seminhematol.2014.08.004. View

13.

Guess T, Potts C, Bhat P, Cartailler J, Brooks A, Holt C . Distinct Patterns of Clonal Evolution Drive Myelodysplastic Syndrome Progression to Secondary Acute Myeloid Leukemia. Blood Cancer Discov. 2022; 3(4):316-329. PMC: 9610896. DOI: 10.1158/2643-3230.BCD-21-0128. View

14.

da Silva-Coelho P, Kroeze L, Yoshida K, Koorenhof-Scheele T, Knops R, van de Locht L . Clonal evolution in myelodysplastic syndromes. Nat Commun. 2017; 8:15099. PMC: 5530598. DOI: 10.1038/ncomms15099. View

15.

Lindsley R, Mar B, Mazzola E, Grauman P, Shareef S, Allen S . Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood. 2015; 125(9):1367-76. PMC: 4342352. DOI: 10.1182/blood-2014-11-610543. View

16.

Inoue D, Polaski J, Taylor J, Castel P, Chen S, Kobayashi S . Minor intron retention drives clonal hematopoietic disorders and diverse cancer predisposition. Nat Genet. 2021; 53(5):707-718. PMC: 8177065. DOI: 10.1038/s41588-021-00828-9. View

17.

Xu L, Gu Z, Li Y, Zhang J, Chang C, Pan C . Genomic landscape of CD34+ hematopoietic cells in myelodysplastic syndrome and gene mutation profiles as prognostic markers. Proc Natl Acad Sci U S A. 2014; 111(23):8589-94. PMC: 4060725. DOI: 10.1073/pnas.1407688111. View

18.

Uy G, Duncavage E, Chang G, Jacoby M, Miller C, Shao J . Dynamic changes in the clonal structure of MDS and AML in response to epigenetic therapy. Leukemia. 2016; 31(4):872-881. PMC: 5382101. DOI: 10.1038/leu.2016.282. View

19.

Makishima H, Yoshizato T, Yoshida K, Sekeres M, Radivoyevitch T, Suzuki H . Dynamics of clonal evolution in myelodysplastic syndromes. Nat Genet. 2016; 49(2):204-212. PMC: 8210656. DOI: 10.1038/ng.3742. View

20.

Sabattini E, Bacci F, Sagramoso C, Pileri S . WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview. Pathologica. 2010; 102(3):83-7. View